Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-06-10

Expression analysis of missense pros1 mutations identified in protein s deficient patients

Obiettivo



Research objectives and content
Protein S (PS) is a vitamin K-dependent plasma glycoprotein that inhibits blood coagulation by acting as the cofactor of activated protein C in the inactivation of the procoagulant factors Va and VIIIa. In plasma, around a 60% of PS forms a noncovalent complex with the Beta-chain of the complement C4b-binding protein and only the remaining 40% of PS circulates as free protein and is active as a cofactor of APC. Inherited PS deficiency is an autosomal dominant disease associated with an increased risk for the development of venous thrombotic events, which confirms the physiological role of PS as an antithrombotic protein. The human PS gene (PROS1) spans about 80kb of genomic DNA on the centromeric region of chromosome 3 and it contains 15 exons which are transcribed in a 3.5 kb mRNA. Direct analysis of PROS1 in PS deficient families has revealed the presence of several different missense mutations which are associated with one of two different abnormal PS phenotypes: type I (reduced plasma concentration of PS antigen) or type III (reduced plasma concentrations of the free and active form of PS). Many of these mutations have been identified by our group in Spanish PS deficient families. The reason why such protein S amino acids substitutions result in the PS deficient phenotype is as yet unknown and although molecular modelling studies may predict the role of these and other amino acids in the structure and function of PS, the definite proof of this role will come from expression studies of their respective protein S mutants. The main objective of the proposed research project is to perform the expression studies required to analyse the molecular fate of several PROS1 missense mutations that have been identified in Spanish patients with thrombosis associated with type I or type III PS deficiency. With this purpose an expression vector containing the normal or the mutated PROS1 cDNAs will be constructed, transfected into a mammalian cell line that allows for a correct post-translational processing of protein S and their expression products will be analysed after culture of the transfected cells.
Training content (objective, benefit and expected impact)
Training in the methodologies required for recombinant gene expression studies will be obtained. Particularly, this will be: vector construction, mutagenesis of cloned cDNAs, cell transfection, cell culture and analysis of the expression products. Knowledge and experience in these methodologies will be of great benefit for future mutant analysis, either in the PS gene or in other genes associated with thromboembolic or other inherited diseases.
Links with industry / industrial relevance (22)
The results of these studies could be of interest in the pharmaceutical industry for the production of recombinant protein S molecules with therapeutical properties in the treatment of venous thrombotic diseases. The availability of recombinant PS mutants can also be of use to determine the sensibility of PS assays for common PS missense mutantions. In particular, this can be applied to analyse the sensibility for these mutants PS molecules of the new free PS antigen assay that has been recently described and is being developed in Dr. Dahlbdck laboratory.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

RGI - Research grants (individual fellowships)

Coordinatore

LUND UNIVERSITY
Contributo UE
Nessun dato
Indirizzo
Wallenberg laboratoriet, University Hospital
221 85 LUND
Svezia

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (1)

Il mio fascicolo 0 0